UNSPSC 51201826: Impromidine hydrochloride

This classification denotes an anti-lipidemic agent with the molecular formula C14H23N7S.3ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E57WP5Y41J, chemically known as guanidine, n-(3-(1h-imidazol-4-yl)propyl)-n'-(2-(((5-methyl-1h-imidazol-4-yl)methyl)thio)ethyl)-, trihydrochloride, but more generally known as impromidine hydrochloride, which bears US NIH Compound Identifier 163318.

European Medicines Agency schedules impromidine hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08159MIG. Most nations, for tariff purposes, schedule impromidine hydrochloride under HS 29332990. Impromidine hydrochloride bears US NLM identifiers UMLS ID C0886650 and NCI Concept Code C65903. SMILES: CC1C(NC[NH]1)CSCCNC(=N)NCCCC2C[NH]CN2.CL.CL.CL.

UNSPSC 51201826 Impromidine hydrochloride is a Commodity code that captures pharmaceutical products, though recent state and local solicitation activity under this code shows minimal relevant procurement. The single recent opportunity posted under this code—a Mississippi State Department of Health notice for Yellow Fever Vaccine from Sanofi Pasteur, Inc.—does not align with the code's nominal scope of impromidine hydrochloride, a histamine H2-receptor agonist. State and local health departments and related agencies represent the primary issuing-body type for pharmaceutical procurements in this family, but the available record does not support a pattern of activity specifically tied to impromidine hydrochloride or closely related compounds.

The Mississippi State Department of Health posted a sole source procurement notice (Solicitation 3150006922) on July 13, 2026, with an objection deadline of August 3, 2026, for Yellow Fever Vaccine—a product outside the stated code scope. The notice invited written objections to the sole source designation, directed to Cynthia Brasher at the department's Purchasing Department, demonstrating that alternative vendors could supply the vaccine. The notice did not specify quantity, contract term, estimated value, or pricing. This code shows little current activity aligned with impromidine hydrochloride procurement at the state and local level; firms pursuing pharmaceutical supply opportunities should monitor health department solicitations across states for category-specific RFPs and RFQs rather than rely on this code's recent posting record.